Patient-Reported Symptoms and Quality of Life: A Real-World Survey of Patients With Muscle Invasive Bladder Cancer
Moderator
Abin Koshy, PharmD, Pfizer, New Hyde Park, NY, United States
Speakers
Jens Bedke; Anthony Eccleston, MSc; Julia Brinkmann; Jane Chang, MPH; Neil Milloy; Laure Manuel; Jacob Skilling; Emilia Biondi, Bollington, United Kingdom; Elliott Brown; Caitlin Ford; Yair Lotan
OBJECTIVES: To understand patients’ perspectives on health-related quality of life (HRQoL) using patient-reported outcome measures (PROMs) in patients with muscle invasive bladder cancer (MIBC) who received radical cystectomy (RC; group A) compared to those who refused/were ineligible for RC (group B).
METHODS: Data were drawn from the Adelphi Real World MIBC Disease Specific Programme™, a cross-sectional survey, with retrospective data collection of physicians and patients in France, Germany, Spain, Italy and the United Kingdom from December 2023 to May 2024. Patients voluntarily completed a patient self-completion form.
PROMs included: EQ-5D-5L (German Tariff: range, 1 [full health] to 0 [death]), EORTC-QLQ-C30 and MIBC module (EORTC-QLQ-BLM30) where scores range from 0-100, with higher scores indicating higher functioning while for symptomology greater symptom severity. Analyses were descriptive.
RESULTS: Overall, 396 MIBC patients reported data (n=208; group A and n=188; group B). At data collection mean (standard deviation [SD]) patient age was 70.8 (8.21), and 23% were T0, N0 (31%; group A vs. 15%; group B).
Mean (SD) days between diagnosis and data collection was 268.4 (161.35; group A) vs 199.1 (144.89; group B).
Mean (SD) EQ-5D-5L index was 0.83 (0.16; group A) vs 0.75 (0.22; group B).
Mean (SD) EORTC global health status score was 56.5 (18.66; group A) vs 51.4 (19.71; group B). Mean (SD) symptoms score for fatigue was 37.0 (24.97; group A) vs 45.6 (26.89; group B).
Using the EORTC-QLQ-BLM30, mean (SD) scores in group A vs group B were 30.7 (27.77) vs 23.8 (25.69) for abdominal bloating and flatulence, 28.7 (25.44) vs 28.1 (25.53) for sexual functioning, and 46.3 (24.39) vs 49.2 (26.54) for future perspective, respectively.
CONCLUSIONS: MIBC impacts patients HRQoL. Patient-reported HRQoL burden is especially high among patients who did not receive a RC, highlighting the need for novel bladder-sparing therapies which reduce symptoms and improve HRQoL.
METHODS: Data were drawn from the Adelphi Real World MIBC Disease Specific Programme™, a cross-sectional survey, with retrospective data collection of physicians and patients in France, Germany, Spain, Italy and the United Kingdom from December 2023 to May 2024. Patients voluntarily completed a patient self-completion form.
PROMs included: EQ-5D-5L (German Tariff: range, 1 [full health] to 0 [death]), EORTC-QLQ-C30 and MIBC module (EORTC-QLQ-BLM30) where scores range from 0-100, with higher scores indicating higher functioning while for symptomology greater symptom severity. Analyses were descriptive.
RESULTS: Overall, 396 MIBC patients reported data (n=208; group A and n=188; group B). At data collection mean (standard deviation [SD]) patient age was 70.8 (8.21), and 23% were T0, N0 (31%; group A vs. 15%; group B).
Mean (SD) days between diagnosis and data collection was 268.4 (161.35; group A) vs 199.1 (144.89; group B).
Mean (SD) EQ-5D-5L index was 0.83 (0.16; group A) vs 0.75 (0.22; group B).
Mean (SD) EORTC global health status score was 56.5 (18.66; group A) vs 51.4 (19.71; group B). Mean (SD) symptoms score for fatigue was 37.0 (24.97; group A) vs 45.6 (26.89; group B).
Using the EORTC-QLQ-BLM30, mean (SD) scores in group A vs group B were 30.7 (27.77) vs 23.8 (25.69) for abdominal bloating and flatulence, 28.7 (25.44) vs 28.1 (25.53) for sexual functioning, and 46.3 (24.39) vs 49.2 (26.54) for future perspective, respectively.
CONCLUSIONS: MIBC impacts patients HRQoL. Patient-reported HRQoL burden is especially high among patients who did not receive a RC, highlighting the need for novel bladder-sparing therapies which reduce symptoms and improve HRQoL.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD12
Topic
Real World Data & Information Systems
Disease
SDC: Oncology